The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

The investigators hypothesize that the new imaging method Gallium-68-DOTATATE has a higher diagnostic value in the detection of neuroendocrine tumors than the established imaging method Indium-111-Octreoscan. Therefore, the investigators will perform both imaging procedures in patients with suspected or confirmed neuroendocrine tumors. Subsequently, the investigators will compare the diagnostic performance of both methods.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Age ≥ 18 years

Signed written informed consent with full understanding of the study procedures and the investigational nature of the study

Patient referred to Indium-111-pentetreotide scintigraphy., which was performed as part of clinical routine care

Inclusion criteria specific for cases only

Histologically established GEP-NET (new or recurrent)

Tumor mass remaining after initial biopsy or surgery

Inclusion criteria specific for controls only

5.6. Suspicion of any NET (new or recurrent) but no established diagnosis or established diagnosis of any NET (new or recurrent) but no remaining tumor mass after surgery

Exclusion Criteria

Previous inclusion in the same study with the following exception: a patient may be included as case if she/he was previously included as control

Gastric type 2 ECL cell neuroendocrine tumors

Pregnant or nursing women

Known intolerance to any protocol required diagnostic intervention

Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the study and to formulate his/her own wishes correspondingly

Exclusion criteria specific for controls only

Patients for whom it remains unclear whether the tumor was completely removed

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02078843